Compounds > butyryl-n-trihexylcitrate
Page last updated: 2024-09-04

butyryl-n-trihexylcitrate and paclitaxel

butyryl-n-trihexylcitrate has been researched along with paclitaxel in 4 studies

Compound Research Comparison

Studies
(butyryl-n-trihexylcitrate)		Trials
(butyryl-n-trihexylcitrate)		Recent Studies (post-2010)
(butyryl-n-trihexylcitrate)		Studies
(paclitaxel)		Trials
(paclitaxel)		Recent Studies (post-2010) (paclitaxel)
122531,8745,72915,395

Protein Interaction Comparison

ProteinTaxonomybutyryl-n-trihexylcitrate (IC50)paclitaxel (IC50)
Integrin beta-3Homo sapiens (human)0.034
Integrin alpha-V Homo sapiens (human)0.034
ATP-dependent translocase ABCB1Homo sapiens (human)2.598
Botulinum neurotoxin type A Clostridium botulinum5.2
UDP-glucuronosyltransferase 2B7Homo sapiens (human)4.9
UDP-glucuronosyltransferase 1-6Homo sapiens (human)4.9
Substance-K receptorHomo sapiens (human)6.125
UDP-glucuronosyltransferase 1A1 Homo sapiens (human)4.9
UDP-glucuronosyltransferase 1A4Homo sapiens (human)4.9
UDP-glucuronosyltransferase 2B10 Homo sapiens (human)4.9
Delta-type opioid receptorHomo sapiens (human)4.202
Tyrosine-protein kinase MerHomo sapiens (human)4.9
Tubulin beta-3 chainHomo sapiens (human)0.0082
Beta-tubulin Leishmania donovani1
Nucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)7.9433
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)0.26
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)0.28

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bayer, G; Byrne, RA; Hartwig, S; Joner, M; Joost, A; Radke, PW; Steigerwald, K; Wittchow, E1
Bruno, H; Erglis, A; Graf, K; Hehrlein, C; Hoffman, S; Kornowski, R; Merkely, B; Naber, C; Richardt, G; Slagboom, T; Toelg, R; Witzenbichler, B1
Lammer, J; Scheinert, D; Schulte, KL; Tepe, G; Zeller, T1
Almalla, M; Burgmaier, M; Reith, S; Schröder, J; Vogt, F1

Trials

1 trial(s) available for butyryl-n-trihexylcitrate and paclitaxel

ArticleYear
Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial.
    Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 2015, Volume: 22, Issue:1

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Ankle Brachial Index; Austria; Butyrates; Cardiovascular Agents; Coated Materials, Biocompatible; Excipients; Female; Femoral Artery; Follow-Up Studies; Germany; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Radiography; Treatment Outcome

2015

Other Studies

3 other study(ies) available for butyryl-n-trihexylcitrate and paclitaxel

ArticleYear
Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipients.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2011, Oct-30, Volume: 7, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Animals; Butyrates; Cardiovascular Agents; Citrates; Coated Materials, Biocompatible; Coronary Angiography; Coronary Vessels; Equipment Design; Excipients; Female; Iohexol; Lecithins; Male; Models, Animal; Paclitaxel; Sus scrofa; Time Factors; Wound Healing

2011
Coronary artery treatment with paclitaxel-coated balloon using a BTHC excipient: clinical results of the international real-world DELUX registry.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2014, Volume: 10, Issue:5

    Topics: Aged; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Butyrates; Coronary Restenosis; Excipients; Female; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Registries

2014
Long-term clinical outcomes after treatment of stent restenosis with two drug-coated balloons.
    Coronary artery disease, 2018, Volume: 29, Issue:8

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Butyrates; Cardiac Catheters; Cardiovascular Agents; Coated Materials, Biocompatible; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Equipment Design; Excipients; Female; Humans; Iohexol; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Percutaneous Coronary Intervention; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome

2018